Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1027267

	registered interest
	date	17/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when all sites selected for the pre-exposure prophylaxis impact trial will be open to participant recruitment.
	tabling member constituency	Kingston upon Hull North
	tabling member printed	Diana Johnson
	uin	202736
	answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>The 10,000 places allocated to the Pre-Exposure Prophylaxis Impact Trial undertaken across England were determined on the basis of the numbers likely to address the study objectives. The figure was revised upwards to 13,000 in 2018. Any further increase in trial numbers would need to be considered against the likelihood that the trial objectives would not be met or revised objectives are felt to be necessary.</p><p> </p><p><ins class="ministerial">Of the current 152 sites that expressed an interest in taking part,</ins><del class="ministerial">All planned</del> 140 trial sites have now opened. The current overview of the site status can be seen on the trial website at the following link:</p><p> </p><p><a href="https://www.prepimpacttrial.org.uk/join-the-trial" target="_blank">https://www.prepimpacttrial.org.uk/join-the-trial</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/12/2018 13:02:31 question first ministerially corrected 23/01/2019 12:03:23 answering member 4067 label Biography information for Steve Brine previous answer version 93031 answering member constituency Winchester answering member printed Steve Brine answering member 4067 label Biography information for Steve Brine
	tabling member	1533 label Biography information for Dame Diana Johnson

1027266

	registered interest
	date	17/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of increasing the number of places available on the pre-exposure prophylaxis impact trial for gay and bisexual men.
	tabling member constituency	Kingston upon Hull North
	tabling member printed	Diana Johnson
	uin	202735
	answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>The 10,000 places allocated to the Pre-Exposure Prophylaxis Impact Trial undertaken across England were determined on the basis of the numbers likely to address the study objectives. The figure was revised upwards to 13,000 in 2018. Any further increase in trial numbers would need to be considered against the likelihood that the trial objectives would not be met or revised objectives are felt to be necessary.</p><p> </p><p>All planned 140 trial sites have now opened. The current overview of the site status can be seen on the trial website at the following link:</p><p> </p><p><a href="https://www.prepimpacttrial.org.uk/join-the-trial" target="_blank">https://www.prepimpacttrial.org.uk/join-the-trial</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 202736 question first answered 20/12/2018 13:02:31 answering member 4067 label Biography information for Steve Brine
	tabling member	1533 label Biography information for Dame Diana Johnson

523084

	registered interest
	date	06/06/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent representations he has received on the possible benefits of pre-exposure prophylaxis for preventing HIV exposure.
	tabling member constituency	Kingston upon Hull North
	tabling member printed	Diana Johnson
	uin	39481
	answer	answer is ministerial correction date of answer 14/06/2016 answer text <p>The Department has received various representations from Members of Parliament, Peers, stakeholders and some individual members of the public.</p><p><strong> </strong></p> answering member constituency Battersea answering member printed Jane Ellison question first answered 14/06/2016 15:06:07 answering member 3918 label Biography information for Jane Ellison
	tabling member	1533 label Biography information for Dame Diana Johnson

676053

	registered interest
	date	20/01/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how much in legal and other costs his Department has spent on (a) high court and (b) court of appeal cases related to the commissioning of pre-exposure prophylaxis for HIV prevention.
	tabling member constituency	Kingston upon Hull North
	tabling member printed	Diana Johnson
	uin	61076
	answer	answer is ministerial correction date of answer 27/01/2017 answer text <p>The Department’s costs in relation to this case are not yet available.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 27/01/2017 12:02:49 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1533 label Biography information for Dame Diana Johnson

864442

	registered interest
	date	15/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps (a) his Department, (b) NHS England and (c) Public Health England is taking to ensure the equity of access to antiretoroviral therapy in the regions.
	tabling member constituency	Kingston upon Hull North
	tabling member printed	Diana Johnson
	uin	132925
	answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>Estimates of undiagnosed HIV infection are not available by Nomenclature of Territorial Units for Statistics (NUTS) 1 region.</p><p><strong> </strong></p><p>There may be some regional differences in treatment rates or drugs used based on variations in patient demographics or the available drug contracts.</p><p> </p><p>Regional HIV networks determine prescribing guidelines which align with national commissioning policies for antiretroviral therapies. These guidelines are overseen by the HIV Clinical Reference Group – which includes strong patient representation - who provide clinical advice on HIV treatment issues and raise concerns from the community should there be perceived issue around equitable access.</p><p> </p><p>Working closely with Public Health England (PHE), NHS England has produced a clinical dashboard that summarises clinical performance at the trust level. PHE prepares and analyses all the data that feeds into the Clinical Reference Group HIV dashboard. Two dashboard indicators measure anti-retroviral therapy coverage among all people accessing HIV care and among people with a low CD4 count (indicative of immunosuppression). Further information on the dashboard is available here:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/npc-crg/spec-dashboards/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/spec-dashboards/</a></p><p> </p><p> </p><p>Data are not available by NUTS for the proportion of people living with diagnosed HIV infection who are not receiving antiretroviral therapy treatment.</p><p> </p><p>Antiretroviral therapy is now so effective that people receiving treatment can expect to have a near normal life expectancy. Consequently, the proportion of people receiving treatment continues to rise each year since death rates remain low. The higher antiretroviral therapy coverage rate observed in some regions is partially due to the longer history of the epidemic in these areas.</p><p> </p><p> </p><p>British HIV Association guidelines have progressively reduced the threshold at which patients may begin antiretroviral therapy. In 2018, NHS England announced routine commissioning of ‘Immediate Access to Antiretroviral Therapy’ from 1 April 2018.</p><p> </p><p><a href="https://www.england.nhs.uk/publication/clinical-commissioning-policy-immediate-antiretroviral-therapy-for-treatment-of-hiv-1-in-adults-and-adolescents/" target="_blank">https://www.england.nhs.uk/publication/clinical-commissioning-policy-immediate-antiretroviral-therapy-for-treatment-of-hiv-1-in-adults-and-adolescents/</a></p><p> </p><p>This enables all patients to access treatment at the point of diagnosis or at the time the patient wishes to commence treatment. It has also clarified the position on the funding of antiretroviral therapy for immediate treatment among patients newly diagnosed with HIV.</p><p> </p><p>NHS England and PHE keep under review data on the rates of uptake of antiretroviral treatment and will continue to do so to identify any unwarranted variation.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 132924 132926 132927 question first answered 20/03/2018 16:36:27 answering member 4067 label Biography information for Steve Brine
	tabling member	1533 label Biography information for Dame Diana Johnson

864443

	registered interest
	date	15/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what proportion of people diagnosed with HIV infection are not receiving antiretroviral treatment by NUTS 1 region in each year since 2013-14.
	tabling member constituency	Kingston upon Hull North
	tabling member printed	Diana Johnson
	uin	132926
	answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>Estimates of undiagnosed HIV infection are not available by Nomenclature of Territorial Units for Statistics (NUTS) 1 region.</p><p><strong> </strong></p><p>There may be some regional differences in treatment rates or drugs used based on variations in patient demographics or the available drug contracts.</p><p> </p><p>Regional HIV networks determine prescribing guidelines which align with national commissioning policies for antiretroviral therapies. These guidelines are overseen by the HIV Clinical Reference Group – which includes strong patient representation - who provide clinical advice on HIV treatment issues and raise concerns from the community should there be perceived issue around equitable access.</p><p> </p><p>Working closely with Public Health England (PHE), NHS England has produced a clinical dashboard that summarises clinical performance at the trust level. PHE prepares and analyses all the data that feeds into the Clinical Reference Group HIV dashboard. Two dashboard indicators measure anti-retroviral therapy coverage among all people accessing HIV care and among people with a low CD4 count (indicative of immunosuppression). Further information on the dashboard is available here:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/npc-crg/spec-dashboards/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/spec-dashboards/</a></p><p> </p><p> </p><p>Data are not available by NUTS for the proportion of people living with diagnosed HIV infection who are not receiving antiretroviral therapy treatment.</p><p> </p><p>Antiretroviral therapy is now so effective that people receiving treatment can expect to have a near normal life expectancy. Consequently, the proportion of people receiving treatment continues to rise each year since death rates remain low. The higher antiretroviral therapy coverage rate observed in some regions is partially due to the longer history of the epidemic in these areas.</p><p> </p><p> </p><p>British HIV Association guidelines have progressively reduced the threshold at which patients may begin antiretroviral therapy. In 2018, NHS England announced routine commissioning of ‘Immediate Access to Antiretroviral Therapy’ from 1 April 2018.</p><p> </p><p><a href="https://www.england.nhs.uk/publication/clinical-commissioning-policy-immediate-antiretroviral-therapy-for-treatment-of-hiv-1-in-adults-and-adolescents/" target="_blank">https://www.england.nhs.uk/publication/clinical-commissioning-policy-immediate-antiretroviral-therapy-for-treatment-of-hiv-1-in-adults-and-adolescents/</a></p><p> </p><p>This enables all patients to access treatment at the point of diagnosis or at the time the patient wishes to commence treatment. It has also clarified the position on the funding of antiretroviral therapy for immediate treatment among patients newly diagnosed with HIV.</p><p> </p><p>NHS England and PHE keep under review data on the rates of uptake of antiretroviral treatment and will continue to do so to identify any unwarranted variation.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 132924 132925 132927 question first answered 20/03/2018 16:36:27 answering member 4067 label Biography information for Steve Brine
	tabling member	1533 label Biography information for Dame Diana Johnson

864444

	registered interest
	date	15/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the reasons for regional differences in the uptake of antiretroviral therapy.
	tabling member constituency	Kingston upon Hull North
	tabling member printed	Diana Johnson
	uin	132927
	answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>Estimates of undiagnosed HIV infection are not available by Nomenclature of Territorial Units for Statistics (NUTS) 1 region.</p><p><strong> </strong></p><p>There may be some regional differences in treatment rates or drugs used based on variations in patient demographics or the available drug contracts.</p><p> </p><p>Regional HIV networks determine prescribing guidelines which align with national commissioning policies for antiretroviral therapies. These guidelines are overseen by the HIV Clinical Reference Group – which includes strong patient representation - who provide clinical advice on HIV treatment issues and raise concerns from the community should there be perceived issue around equitable access.</p><p> </p><p>Working closely with Public Health England (PHE), NHS England has produced a clinical dashboard that summarises clinical performance at the trust level. PHE prepares and analyses all the data that feeds into the Clinical Reference Group HIV dashboard. Two dashboard indicators measure anti-retroviral therapy coverage among all people accessing HIV care and among people with a low CD4 count (indicative of immunosuppression). Further information on the dashboard is available here:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/npc-crg/spec-dashboards/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/spec-dashboards/</a></p><p> </p><p> </p><p>Data are not available by NUTS for the proportion of people living with diagnosed HIV infection who are not receiving antiretroviral therapy treatment.</p><p> </p><p>Antiretroviral therapy is now so effective that people receiving treatment can expect to have a near normal life expectancy. Consequently, the proportion of people receiving treatment continues to rise each year since death rates remain low. The higher antiretroviral therapy coverage rate observed in some regions is partially due to the longer history of the epidemic in these areas.</p><p> </p><p> </p><p>British HIV Association guidelines have progressively reduced the threshold at which patients may begin antiretroviral therapy. In 2018, NHS England announced routine commissioning of ‘Immediate Access to Antiretroviral Therapy’ from 1 April 2018.</p><p> </p><p><a href="https://www.england.nhs.uk/publication/clinical-commissioning-policy-immediate-antiretroviral-therapy-for-treatment-of-hiv-1-in-adults-and-adolescents/" target="_blank">https://www.england.nhs.uk/publication/clinical-commissioning-policy-immediate-antiretroviral-therapy-for-treatment-of-hiv-1-in-adults-and-adolescents/</a></p><p> </p><p>This enables all patients to access treatment at the point of diagnosis or at the time the patient wishes to commence treatment. It has also clarified the position on the funding of antiretroviral therapy for immediate treatment among patients newly diagnosed with HIV.</p><p> </p><p>NHS England and PHE keep under review data on the rates of uptake of antiretroviral treatment and will continue to do so to identify any unwarranted variation.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 132924 132925 132926 question first answered 20/03/2018 16:36:27 answering member 4067 label Biography information for Steve Brine
	tabling member	1533 label Biography information for Dame Diana Johnson